Skip to main content

Table 1 Demographic characteristics at study entry

From: A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

Characteristic Mixed Motavizumab/Palivizumab (n = 83) Mixed Palivizumab/Motavizumab (n = 84) Motavizumab Only (n = 93) Total (N = 260)
Age, mo     
   Mean (SD) 3.7 (3.1) 3.4 (2.3) 3.9 (2.4) 3.7 (2.6)
Gestational age at birth, wk     
   Mean (SD) 31.0 (2.6) 31.3 (2.9) 30.9 (2.7) 31.1 (2.7)
Sex, n (%)     
   Male 51 (61.4) 43 (51.2) 48 (51.6) 142 (54.6)
Race/ethnicity, n (%)     
   White/Non-Hispanic 23 (27.7) 20 (23.8) 28 (30.1) 71 (27.3)
   Hispanic 53 (63.9) 56 (66.7) 57 (61.3) 166 (63.8)
   Other 7 (8.4) 8 (9.5) 8 (8.6) 23 (8.8)
Weight, kg     
   Mean (SD) 4.6 (2.0) 4.4 (1.8)a 4.7 (1.7) 4.6 (1.8)
CLD present, n (%) 11 (13.3) 14 (16.7) 16 (17.2) 41 (15.8)
  1. an = 83 (weight was not recorded for one subject).